• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tvardi Therapeutics Inc.

    8/8/25 4:30:09 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVRD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tvardi Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    140755208

    (CUSIP Number)


    04/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    140755208


    1Names of Reporting Persons

    Sporos Bioventures LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    837,636.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    837,636.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    837,636.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.95 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tvardi Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    3 Sugar Creek Ctr Blvd, Ste 525, Sugar Land, Texas, 77478
    Item 2. 
    (a)Name of person filing:

    Sporos Bioventures LLC
    (b)Address or principal business office or, if none, residence:

    3139 West Holcombe Blvd, Houston, Texas, 77025
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    140755208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Sporos Bioventures LLC directly owns 837,636 shares of Common Stock
    (b)Percent of class:

    8.95  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    837,636

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    837,636

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sporos Bioventures LLC
     
    Signature:/s/ Stephen Rubino
    Name/Title:Stephen Rubino, Chief Executive Officer
    Date:08/08/2025
    Get the next $TVRD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TVRD

    DatePrice TargetRatingAnalyst
    7/14/2025$62.00Outperform
    Raymond James
    7/11/2025$52.00Overweight
    Cantor Fitzgerald
    6/12/2025$78.00Overweight
    Piper Sandler
    5/21/2025$65.00Outperform
    Oppenheimer
    5/15/2025$55.00Buy
    BTIG Research
    More analyst ratings

    $TVRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Tvardi Therapeutics with a new price target

    Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00

    7/14/25 8:56:16 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Tvardi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00

    7/11/25 8:16:19 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tvardi Therapeutics with a new price target

    Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00

    6/12/25 7:57:03 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company

    8/21/25 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

    On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic

    8/14/25 4:01:00 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

    Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo

    7/15/25 8:00:00 AM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TVRD
    SEC Filings

    View All

    $TVRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    8/14/25 4:31:59 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tvardi Therapeutics Inc.

    10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)

    8/14/25 4:10:53 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tvardi Therapeutics Inc.

    SCHEDULE 13G - Tvardi Therapeutics, Inc. (0001346830) (Subject)

    8/8/25 4:30:09 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tweardy Samuel David disposed of 631,316 shares (SEC Form 4)

    4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    8/5/25 8:03:49 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hall Wallace L Jr was granted 246,756 shares (SEC Form 4)

    4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    5/2/25 6:19:16 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Wirk Shaheen was granted 439,194 shares (SEC Form 4)

    4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

    5/2/25 6:12:20 PM ET
    $TVRD
    Biotechnology: Pharmaceutical Preparations
    Health Care